Agilent Technologies, Inc. (NYSE:A) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Agilent Technologies has received an average recommendation of "Moderate Buy" from twelve research firms, with six analysts rating it as a hold and six as a buy.
• Analysts have lowered their price targets for Agilent Technologies, with JPMorgan reducing it from $160 to $155 and UBS from $150 to $130, while Wells Fargo increased its target from $140 to $150.
• The company's recent quarterly earnings report showed an EPS of $1.37, meeting expectations, with a revenue increase of 10.1% year-over-year to $1.74 billion.

Agilent Technologies, Inc. (NYSE:A - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve research firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $140.0833.

A number of equities analysts recently issued reports on A shares. JPMorgan Chase & Co. lowered their price target on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Wells Fargo & Company upped their price target on Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a report on Monday. Wall Street Zen downgraded Agilent Technologies from a "buy" rating to a "hold" rating in a report on Friday, September 5th. Evercore ISI lowered their price target on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a report on Thursday, August 28th. Finally, UBS Group lowered their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $125.68 on Tuesday. Agilent Technologies has a one year low of $96.43 and a one year high of $153.84. The company has a market cap of $35.63 billion, a PE ratio of 29.50, a P/E/G ratio of 3.83 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The business has a 50-day simple moving average of $119.89 and a 200-day simple moving average of $115.77.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the company posted $1.32 earnings per share. The business's revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities research analysts forecast that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Agilent Technologies

Several large investors have recently modified their holdings of A. Whipplewood Advisors LLC boosted its holdings in shares of Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock valued at $29,000 after acquiring an additional 186 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock valued at $30,000 after acquiring an additional 192 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of Agilent Technologies in the first quarter valued at approximately $30,000. Opal Wealth Advisors LLC acquired a new stake in shares of Agilent Technologies in the first quarter valued at approximately $31,000. Finally, Ransom Advisory Ltd acquired a new stake in shares of Agilent Technologies in the first quarter valued at approximately $32,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.